www.fdanews.com/articles/127123-neopharm-gets-fda-orphan-drug-designation-for-ipf-treatment
NeoPharm Gets FDA Orphan Drug Designation for IPF Treatment
May 17, 2010
NeoPharm announced Monday that the Office of Orphan Products Development of the FDA has granted orphan-drug designation for IL13-PE38QQR for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
MarketWatch
MarketWatch